Comparison between Reirradiation by Stereotactic Body Radiation Therapy and Moderately Hypofractionated Radiotherapy in Combination with Temozolomide for Treatment of Recurrent High Grade Glioma
Objective:
High grade glioma (HGG) often recurs and lacks a standard treatment. This study compared the effectiveness and side effects of two re-irradiation methods.
Methods:
Forty patients with recurrent HGG were divided into two groups. One received 30 Gy/10f/2w radiotherapy, and the other received stereotactic body radiotherapy (SBRT) 30 Gy/5f/1w, both with concurrent temozolomide (TMZ). Progression free survival (PFS) and overall survival (OS) were calculated, and brain MRI and toxicity were monitored.
Results:
The median PFS after recurrence was 6.4 months, median OS after recurrence was 8.6 months, and median total OS from diagnosis was 18.5 months. There was a significant improvement in PFS in the SBRT group, but no significant difference in OS. Patients tolerated the treatment well, with manageable acute and subacute side effects.
Conclusion:
Both re-irradiation methods were safe and effective, with SBRT showing a significant improvement in PFS.
